Table 1.
Baseline characteristics of patients with HCC undergoing TACE.
| Variable | All patients(n=237) | Recommended TACE subgroup (n=126) |
|---|---|---|
| Median age, years (IQR) | 70 (62-75) | 70 (63-75) |
| Gender, n (%) | ||
| Female | 197 (16.9) | 18 (14.3) |
| Male | 40 (83.1) | 108 (85.7) |
| Etiology, n | ||
| Alcoholic | 112 | 57 |
| Hepatitis C | 38 | 19 |
| Hepatitis B | 24 | 16 |
| NASH | 23 | |
| Hemochromatosis | 5 | 3 |
| AIH/PBC/PSC | 4 | 3 |
| Unknown/Other | 23 | 11 |
| Child-Pugh stage, n (%) | ||
| A | 94 (39.7) | 54 (42.9) |
| B | 94 (39.7) | 57 (45.2) |
| C | 21 (8.8) | 0 |
| No cirrhosis | 28 (11.8) | 15 (11.9) |
| BCLC stage, n (%) | ||
| 0 | 0 | 0 |
| A | 43 (18.1) | 0 |
| B | 126 (53.2) | 126 (100.0) |
| C | 48 (20.3) | 0 |
| D | 20 (8.4) | 0 |
| Median max. tumor size, cm (IQR) | 4.1 (2.8-6.2) | 4.2 (3.0-5.9) |
| Tumor number, n (%) | ||
| Unifocal | 55 (23.2) | 0 |
| Multifocal | 167 (70.5) | 120 (95.2) |
| Diffuse growth pattern, n (%) | 15 (6.3) | 6 (4.8) |
| Median albumin level, g/L (IQR) | 32 (28-36) | 33 (29-36) |
| Median lymphocyte count, per mm3 (IQR) | 1221 (831-1599) | 1279 (841-1743) |
| Median cholesterol level, mg/dl (IQR) | 165 (137-203) | 167 (138-213) |
| Median bilirubin level, mg/dl (IQR) | 1.3 (0.8-2.1) | 1.2 (0.8-1.9) |
| Median platelet count, per nl (IQR) | 128 (86-193) | 123 (82-188) |
| Median AST level, U/L (IQR) | 63 (45-97) | 62 (47-87) |
| Median ALT level, U/L (IQR) | 42 (28-62) | 41 (27-61) |
| Median INR (IQR) | 1.2 (1.1-1.3) | 1.1 (1.0-1.3) |
| Median AFP level, ng/ml (IQR) | 44 (8.5-744.5) | 47 (8.8-536.3) |
| Type of TACE | ||
| cTACE | 82 (34.6) | 35 (27.8) |
| DEB-TACE | 155 (65.4) | 91 (72.2) |